Specifically: “ Although our pharmaceutical armamentarium is very good at the moment (the combination of statin-ezetimibe-proprotein convertase subtilisin/kexin type 9 [PCSK9] can reduce LDL cholesterol [LDL-C] levels by 85%), new drugs are emerging through the different pitfalls of current drugs.”